Home Query References Browse Contact

18 patient data entries in database for clusters P587L and 1.

Entry
#
Mutations
allele 1allele 2
Clinical representationSymptomsAge groupAge of onsetAge of patientAge of deathReference
49R853Q1
T251I
P587L2
Developmental delay, dementia, lactic acidosis, microcephaly, FTT, hearing loss, abnormal MRI.
-lactic acidosis
-failure to thrive
-developmental delay
-dementia
-microcephaly
-hearing loss
infantile
n/a0.2n/aWong et al, 2008;

[view data]

639G848S1
T251I
P587L2
Alpers
-Alpers syndrome
-encephalopathy
-developmental delay
-epilepsy
infantile
0.5n/an/aWong et al, 2008;

[view data]

284K1191R1
T251I
P587L2
Presented with feeding difficulties and hypotonia, At 4.5 months of age the patient contracted an influenza A infection. Concurrently she experienced hepatomegaly associated with severe hypoglycemia, Abnormalities in liver synthetic function, elevations in liver hepatocellular enzymes, elevated cerebrospinal fluid (CSF) protein, severely reduced mtDNA (3%) in liver. liver failure. She showed signs of ongoing respiratory difficulty, pancreatitis, and renal tubulopathy
-liver failure
-hypotonic
-pancreatitis
-hepatomegaly
-hypoglycemia
-renal tubulopathy
infantile
0.1660.4160.458Lutz et al, 2009;

[view data]

31E1136K1
T251I
P587L2
Vomiting, FTT, hypotonic, lactic acidemia, hypoglycemia, bilateral dense cataracts, hepatomegaly, jaundice, septicemia. infantile hepatocerebral mtDNA depletion. Mother with E1136K allele reported as asymptomatic. Father with T251I/P587L allele reported as asymptomatic.
-lactic acidosis
-hepatocerebral
-jaundice
-failure to thrive
-hypotonic
-vomiting
-hepatomegaly
-hypoglycemia
-septicemia
infantile
0.01n/a0.5Taanman et al, 2009;

[view data]

29K1191R1
T251I
P587L2
Developmental delay/dementia, liver dysfunction, lactic acidosis, fatigue, pancreatitis, cyclic vomiting.
-lactic acidosis
-liver dysfunction
-developmental delay
-dementia
-vomiting
-cyclic vomiting
-pancreatitis
infantile
1n/an/aWong et al, 2008;

[view data]

48N1157S1
T251I
P587L2
N/A (as reported in Tang 2011 JMG)
-no known symptoms
childhood
n/a9n/aTang et al, 2011;

[view data]

421D1184N1
P587L2
T251I
Peripheral neuropathy, PEO, ataxia, epilepsy, fatty liver
-epilepsy
-movement disorder (ataxia)
-peripheral neuropathy
-PEO
childhood
9n/a33Amiot et al, 2009;

[view data]

422D1184N1
T251I
P587L2
Peripheral neuropathy, PEO, fatty liver
-peripheral neuropathy
-PEO
childhood
9n/a30Amiot et al, 2009;

[view data]

24N864S1
P587L2
T251I
MNGIE-like, presented with GI symptoms, ptosis, neuropathy, muscle weakness.
-muscle weakness
-ptosis
juvenile
15n/an/aVan Goethem et al, 2003c;

[view data]

28K1191N1
P587L2
T251I
Stroke/ischaemic episodes, peripheral neuropathy, CPEO, abnormal EMG/NCV, ptosis, muscle weakness, headache/migraine. 167% mtDNA copy number in blood.
-peripheral neuropathy
-muscle weakness
-ptosis
-PEO
-stroke
-headache/ migraine
-ischaemic episodes
adult
n/a39n/aTang et al, 2011;

[view data]

30V1106I1
T251I
P587L2
PEO with myopathy
-myopathy
-PEO
adult
n/a35n/aHorvath et al, 2006;

[view data]

27G848S1
T251I
P587L2
Ocular bulbar weakness, peripheral neuropathy, muscle weakness, CPEO, ptosis, hypothyroidism, abnormal muscle histology, abnormal muscle ultrastructure, large mitochondrial proliferation, ragged red fibers. 96% mtDNA copy number in blood. Patient II-44.
-peripheral neuropathy
-abnormal muscle histology
-abnormal muscle ultrastructure
-ragged red fibers
-muscle weakness
-ptosis
-PEO
-ocular bulbar weakness
-hypothyroidism
adult
n/a81n/aTang et al, 2011;

[view data]

250G848S1
T251I
P587L2
PEO, severe ophthalmoplegia and ptosis, which appeared insidiously and had been present clinically since the age of 55. Muscle biopsy at age 68 revealed mitochondrial myopathy, as well as muscle inflammation with granulomas. multiple mtDNA deletions in muscle tissue.
-myopathy
-mitochondrial myopathy
-ptosis
-PEO
-ophthalmoplegia
adult
5575n/aKollberg et al, 2005;

[view data]

26H932Y1
T251I
P587L2
Peripheral neuropathy, ptosis, muscle weakness, CPK abnormalities. 77% mtDNA copy number in blood.
-peripheral neuropathy
-muscle weakness
-ptosis
-CPK abnormalities
adult
n/a41n/aTang et al, 2011;

[view data]

313G848S1
T251I
P587L2
progressively droopy eyelids, double vision, gait instability, proximal arm weakness, ragged red and ragged blue (succinate dehydrogenase–positive) fibers in about 3% and 6% of all muscle fibers, bilateral ptosis, diplopia, dysarthria, myopathy involving the facial muscles, sensory ataxic polyneuropathy
-polyneuropathy
-ragged red fibers
-myopathy
-ptosis
-diplopia
-dysarthria
adult
n/a80n/aWeiss and Saneto, 2010;

[view data]

503R869Q1
P587L2
T251I
Pareses, ptosis, ataxia, sensory neoropathy, motor neuropathy, axonal neuropathy, demyelinating neuropathy.
-movement disorder (ataxia)
-demyelinating neuropathy
-ptosis
adult
2934n/aHanisch et al, 2014;

[view data]

604G848S1
T251I
P587L2
PEO. cytochrome c oxidase negative ragged red fibers, and multiple mtDNA deletions in skeletal muscle.
-ragged red fibers
-cox-negative
-PEO
adult
n/an/an/aLamantea et al, 2002;

[view data]

25H932Y1
T251I
P587L2
Peripheral neuropathy, exercise intolerance, muscle cramps after exercise, easy fatigability, arrythmia, CPEO, abnormal EMG/NCV, ptosis, cataract, abnormal muscle histology, abnormal muscle ultrastructure, COX deficiency, ragged red fibers. 123% mtDNA copy number in blood.
-peripheral neuropathy
-abnormal muscle histology
-abnormal muscle ultrastructure
-ragged red fibers
-exercise intolerance
-ptosis
-PEO
adult
n/a31n/aTang et al, 2011;

[view data]

1-5 pathogenic cluster assignment of mutations. Mutations displayed without a superscript number are outside of the assigned pathogenic clusters. See cluster definitions for details.

Number of displayed patient cases: 18
Avg age of onset in displayed cases: 25.6
Std dev in onset in displayed cases: 26.1

Search criteria for patient entries:
Mutations Entry IDs Clusters Reference Residue range
Patients for cluster combinations:
First cluster: Second cluster:
Age group: Any Infantile Childhood Juvenile Adult
:.: Privacy Statement :.: Disclaimer :.: Contact Information :.: